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ABSTRACT
Aim. To evaluate five illustrative cases and perform a literature review to identify and describe a working approach to adult-
-onset white matter diseases (WMD).
State of the art. Inherited WMD are a group of disorders often seen in childhood. In adulthood, progressive WMDs are rare, 
apart from the common nonspecific causes of hypertension and other cerebrovascular diseases. The pattern of WMDs on 
neuroimaging can be an important clue to the final diagnosis. Due to the adoption of a combined clinical-imaging-laboratory 
approach, WMD is becoming better recognised, in addition to the rapidly evolving field of genomics in this area. 
Clinical implications. While paediatric WMDs have a well-defined and literature-based clinical-laboratory approach to diag-
nosis, adult-onset WMDs remain an important, pathologically diverse, radiographic phenotype, with different and distinct 
neuropathologies among the various subtypes of WMD. Adult-onset WMDs comprise a wide collection of both acquired and 
inherited aetiologies. While severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neurological complications are emer-
ging, we are as yet unaware of it causing WMD outside of post-anoxic changes. It is important to recognise WMD as a potentially 
undefined acquired or genetic syndrome, even when extensive full genome testing reveals variants of unknown significance. 
Future directions. We propose a combined clinical-imaging-laboratory approach to WMD and continued exploration of 
acquired and genetic factors. Adult-onset WMD, even given this approach, can be challenging because hypertension is often 
comorbid. Therefore, we propose that undiagnosed patients with WMD be entered into multicentre National Organisation for 
Rare Diseases registries to help researchers worldwide make new discoveries that will hopefully translate into future cures.
Key words: adult-onset, genetic analysis, magnetic resonance imaging, white matter disease, white matter hyperintensities, 
COVID-19
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Introduction
White matter diseases (WMD) are a group of brain dis-
orders characterised by either abnormal myelin development 
(hypomyelination) or a loss of acquired myelin (demyelina-
tion). While WMD can be of metabolic origin, the involvement 
of gene coding for proteins (genetic origin) has been strongly 
implicated [1]. 
Furthermore, the widespread use of magnetic resonance 
imaging (MRI) of the brain has increased the recognition of 
adult-onset WMD, and the recognition of WMD has similar-
ly paralleled that of multiple sclerosis [2]. Classic inherited 
WMD must be distinguished from WMD due to acquired 
causes, such as inflammatory or toxic processes, autoimmune 
diseases, infections, neoplasms, and WMD, seen in 50–98% 
of elderly patients, presumably due to small vessel disease [3]. 
While there are increasing reports of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) causing neurological 
complications, we are as yet unaware of it causing WMD [4–6]. 
Furthermore, Köhler et al. [7] and Lynch et al. [8] have recently 
published comprehensive reviews on the diagnosis, categori-
sation, and in some cases, treatment of WMD. 
We here present five challenging illustrative cases that 
demonstrate the complexity and difficulty of investigating 
adult-onset WMDs, especially those of unknown aetiology, 
and we set out a structured approach to diagnosis.
Case 1: cerebral autosomal dominant 
arteriopathy with subcortical infarcts and 
leukoencephalopathy
A 46-year-old man presented to our institution for 
a second opinion on a pituitary tumour. His medical history 
was notable for headaches and cognitive decline, including 
slowed processing speed. The patient was told he might have 
multiple sclerosis in addition to the pituitary tumour and 
was unclear about his underlying condition. His neurologi-
cal examination showed no evidence of visual impairment, 
despite the pituitary tumour. His family history was notable 
for the death of his father and brother from possible stroke. 
MRI of the brain showed distinct anterior temporal pole 
WMD, highly suggestive of cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalop-
athy (CADASIL) (Fig. 1) [9]. 
The neuro-ophthalmology and neurosurgery consultants 
felt that his pituitary tumour was incidental, and recom-
mended the investigation of other causes of his headache and 
cognitive impairment. The patient agreed to undergo genetic 
evaluation and counselling. A commercial single gene test for 
a NOTCH3 gene mutation was positive, thus confirming a di-
agnosis of CADASIL [10]. The patient underwent risk factor 
modification and education for his mild systemic hypertension 
and obstructive sleep apnoea, and his family was advised to 
seek outpatient genetic counselling for their daughter.
Case 2: unknown WMD
A 75-year-old right-handed white woman with a history 
of hypertension, hyperlipidemia, and osteoporosis was fol-
lowed over 11-years in our neurology clinic for intermittent 
progression of numbness and tingling of her left upper and 
lower extremities, as well as cognitive decline with subsequent 
inability to perform activities of daily living. She also reported 
dizziness (dysequilibrium), multiple falls, and left visual field 
difficulty, but no hearing loss. The patient had an unremark-
able birth history, and no history of neurological milestone 
delays or dysmorphic features. She denied a history of tobac-
co, alcohol, or recreational drug use. Her home medications 
included simvastatin 20 mg daily, aspirin 325 mg daily, and 
multivitamins. She had no known family history of WMD. On 
neurological examination, she was alert and oriented, with 
intact speech and cranial nerves. Neuropsychological testing 
revealed cognitive difficulties characterised by impairment in 
executive function, visuospatial skills, and visuoconstruction. 
Auditory attention, verbal learning and memory, and language 
remained essentially intact. 
On confrontational field testing, a progression from left 
quadrantanopia to left homonymous hemianopia was noted and 
confirmed on formal perimetry. Serial funduscopic examinations 
Figure 1. Case 1: T2 FLAIR MRI of the brain. Imaging shows hyper-
intensities in the anterior temporal pole concerning for cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy
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were unremarkable. She gradually developed postural instability, 
left spastic hemiparesis (Medical Research Council grade 4/5), 
and brisk left-sided reflexes (3+) with a left Babinski sign. Myo-
clonus and Hoffman and Tromner signs were absent. There was 
diminished pin-prick sensation, vibration, and proprioception 
in the left upper and lower extremities, with a positive Romberg 
sign and the presence of pseudoathetoid movements. Fine motor 
movements were diminished, and left-sided dysmetria and ataxic 
gait were noted. Orthostatic blood pressure testing was negative 
and autonomic function appeared to be normal.
In 2006, T2 fluid-attenuated inversion recovery (FLAIR) 
MRI of the brain revealed diffuse large confluent white matter 
hyperintensities with abnormal signal intensity in the bilateral 
thalami with right hemisphere brain volume loss and moderate 
enlargement of the right lateral ventricle (ex vacuo), consistent 
with WMD (Fig. 2A). Despite a progression in symptoms, 
imaging in 2014 demonstrated stable volume loss (bifrontal 
ventricular horns [Evan’s index] 43.0 mm; right posterior lat-
eral ventricle 34.8 mm; left posterior lateral ventricle 24.5 mm) 
and confluent cerebral WMD, right > left, with thalamic hy-
perintensities (red arrow) (Fig. 2B)[11]. Magnetic resonance 
spectroscopy demonstrated a decrease in all major metabolites 
(e.g. N-acetyl aspartate, choline, and creatine) consistent with 
nonspecific neuronal loss. A fluorodeoxyglucose PET scan 
of the brain showed globally decreased metabolism in the 
Figure 2. Case 2: T2 FLAIR MRI of the brain. A. Imaging from 2006 demonstrates large areas of confluent hyperintensities involving the 
white matter of the bilateral cerebral hemispheres, right > left. Associated volume loss is greater on the right, with moderate enlargement 
of the right lateral ventricle, particularly posteriorly. B. Imaging from 2014 demonstrates stable volume loss (bifrontal ventricular horns 
[Evan’s index] 43.0 mm; right posterior lateral ventricle 34.8 mm; left posterior lateral ventricle 24.5 mm) and confluent cerebral white 
matter disease, right > left, with thalamic hyperintensities (red arrow)
right hemisphere. Cervical, thoracic, and lumbar MRI were 
unremarkable. Comprehensive testing, including a battery 
of tests for inherited WMD, was negative (Tab. 1). Based on 
the available clinical, laboratory, genetic, and imaging data, 
the patient was diagnosed with WMD of unknown aetiology. 
While this case is unusual, it demonstrates that even 
with advanced imaging and the most up-to-date genetic and 
laboratory repertoires, cases of WMD of unknown aetiology 
still exist that may be the result of sporadic genetic muta-
tion. In these cases, it is important to follow the patient’s 
neurological condition over time and continue to search for 
important clues in the family history or other factors. Similar 
to the management of other neurodegenerative diseases, it is 
necessary to recognise the degree of neurological impairment 
and to prescribe rehabilitative services, such as physical and 
occupational therapy to prevent falls.
Case 3: ‘Chasing the dragon’ 
leukoencephalopathy
A 42-year-old man with a history of opiate addiction 
presented to the emergency department with coma and hypox-
emic respiratory arrest. He required transient intubation and 
mechanical ventilation, and was given naloxone intravenously. 
Upon wakening, he was able to follow commands and was 
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Table 1. Case 2 – Unknown WMD: negative comprehensive testing results
Type of Testing Specific Tests






Autoimmune • Cytoplasmic antineutrophil cytoplasmic antibodies




• Thyroid peroxidase antibody
Infection • Human immunodeficiency virus
• Herpes simplex virus
• Human T-cell lymphotropic virus
• Whipple disease
• Syphilis




• West Nile virus
• John Cunningham virus
• Lyme disease
• Brucella
Mitochondrial/genetic • Normal-to-low venous lactate levels excluded mitochondrial disorder
• Comprehensive leukodystrophy/leukoencephalopathy and mitochondrial DNA genetic testing†
• Whole-exome sequencing revealed a variant of undetermined significance in gene TRPA1
Inherited WMD‡ • Metachromatic leukodystrophy (arylsulfatase A, urine sulfatides)
• Tay-Sachs disease (hexosaminidase A)
• Peroxisomal disorders (long-chain fatty acids)
• Adrenoleukodystrophy (very long-chain fatty acids)
• CADASIL (NOTCH3)
• Childhood ataxia with central hypomyelination or vanishing WMD (EIF2B1-5)
• Hereditary diffuse leukoencephalopathy with axonal spheroids (CSF1R)
• Krabbe disease (galactosylceramidase)
• Organic acidemia (urine organic acid analysis)
Additional testing • EMG/NCV: mild neuropathy
• EEG: delta slowing with occasional sharp activity in the right temporal and parietal regions; no evidence 
of electrographic seizures
• Lumbar puncture: negative for inflammatory causes; negative for oligoclonal bands and immunoglobulin 
G index; negative paraneoplastic panel
• Visual- and brainstem auditory–evoked response tests were normal
CADASIL — cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CSF1R — colony stimulating factor 1 receptor; DNA — deoxyribonucleic acid; EEG — electroencepha-
logram; EIF2B1-5 — eukaryotic translation initiation factor 2b; EMG - electromyography; NCV — nerve conduction velocity; NOTCH3 — neurogenic locus notch homolog protein 3; TRPA1 — transient receptor 
potential ankyrin 1; WMD — white matter disease
†Genes assessed by this test: ABAT, ABCD1, ACOX1, ADAR, ADK, AIMP1, ALDH3A2, APOA1BP, APOPT1, ARCN1, ARSA, ASPA, ASXL2, AUH, B3GALNT2, BCL11B, C20ORFZ, C8ORF38, CCDC88A, CLCN2, CLN6, COL4A1, 
COX15, CSF1R, CTNS, CYP27A1, DARS, DARS2, EARS2, EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5, FA2H, FAM126A, FBXLA, FKRP, GALC, GFAP, GJC2, GPR56, HEPACAM, HSPD1, HTRA1, ITPA, KCNT1, L2HGDH, LMNB1, MARS2, 
MLC1, MLYCD, MPV17, MRPS22, MTFMT, MTTP, NDUFA1, NDUFA10, NDUFA11, NDUFA12, NDUFA2, NDUFA9, NDUFAF1, NDUFAF2, NDUFAF3, NDUFAF4, NDUFB3, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS6, NDUFS7, 
NSUFS8, NDUFV1, NDUFV2, NOTCH3, NUBPL, OMG, PAH, PC, PHGDH, PSAP, PTEN, PUS3, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, SCP2, SDHA, SDHAF1, SDHB, SLC1A2, SLC1A4, SLC16A2, SLC25A12, SLCBA9, 
SNORD118, SNRPB, SON, SOX10, STXBP1, TACO1, TARS2, TBCD, TMTC3, TREM2, TREX1, TUBB4, TUFM, TYMP, TYROBP, VARS2
‡Sjögren-Larsson syndrome, adult polyglucosan body disease, leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation, neuronal ceroid-lipofuscinosis, megalencephalic 
leukoencephalopathy with subcortical cysts, merosin-deficient congenital muscular dystrophy, molybdenum cofactor deficiency, sulfide oxidase deficiency, L-2 hydroxyglutaric aciduria, propionic acidemia, 
adult-onset Canavan disease, and urea cycle deficits were low on the differential
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subsequently extubated and discharged home. However, after 
returning home, his wife reported that he became somnolent 
with intermittent apnoeic episodes overnight. His family 
brought him back to the ED and he was again unresponsive. 
He was reintubated and admitted to the intensive care unit 
and extubated a few days later. The patient, however, remained 
cognitively impaired, and over the next 30 days developed 
a progressive decline in neurological function, including mild 
parkinsonism, poor short-term memory and concentration, 
and behavioural changes including disinhibition and hypersex-
uality. Delayed MRI of the brain showed diffuse white matter 
abnormalities (Supplemental Fig. 1A). Laboratory testing for 
congenital leukoencephalopathies was negative, including 
arylsulfatase A and galactosylceramidase, which excluded 
adult-onset metachromatic leukodystrophy and Krabbe dis-
ease, respectively. While the patient’s clinical condition and 
MRI findings gradually improved over the next six months 
(Supplemental Fig. 1B), he never returned to his prior normal 
neurological baseline.
The patient’s family revealed that he had been inhaling 
heroin vapour, a practice known as “chasing the dragon” which 
can cause acute toxic (or spongiform) leukoencephalopathy 
due to leukotoxins [12–14]. Given the opioid epidemic in 
the United States, this condition could become increasingly 
prevalent. Coenzyme Q10 has been proposed as a potential 
therapeutic agent, along with ongoing anti-opioid efforts to 
reduce disease incidence [15]. 
Case 4: WMD with axonal spheroids and 
pigmented glia
A 37-year-old woman presented with an 11-month history 
of progressive gait dysfunction that had begun with a tendency 
for her left foot to turn in when walking. This progressed to 
considerable balance difficulties. At our first evaluation, her 
neurological examination was notable only for mild ataxia 
involving the left arm and leg. She had a family history of 
similar symptoms that appeared to be dominantly inherited 
paternally. Laboratory testing of metabolic, haematological, 
autoimmune, rheumatological, infectious, and neoplastic 
entities were unremarkable, as was her cerebrospinal fluid 
(CSF) profile. Formal neuropsychological testing showed mild 
cognitive impairment with deficits in complex attention, pro-
cessing speed, and fine motor speed. Non-contrast computed 
tomography (CT) of the head showed bilateral frontoparietal 
atrophy without calcifications. MRI of the brain showed severe 
cortical atrophy of the parietal lobes, and to a lesser extent, 
the frontal lobes, as well as periventricular and subcortical 
hyperintensities on T2 FLAIR sequence (Fig. 3). 
At follow-up 12-months later, she reported difficulty with 
multi-tasking, spelling, and performing mental calculations. 
She was also experiencing slurred speech, worsening balance, 
and difficulty using her left hand, which would move invol-
untarily. Notwithstanding these difficulties, she remained 
independent with her activities of daily living. Neurological 
examination demonstrated dysarthria and left-sided predom-
inant apraxia, ataxia, and spasticity that severely affected her 
gait. Genetic testing demonstrated a pathologic mutation in 
the CSF1R gene.
CSF1R is a tyrosine kinase receptor and is the causative 
gene for axonal spheroids and pigmented glia, also known as 
CSF1R-related leukoencephalopathy. More than 70 mutations 
have been shown to disrupt the function of CSF1R in the brain 
microglia, leading to their dysfunction [16]. Brain biopsy 
was previously the only means of diagnosing this disease; 
however, genetic testing has now removed the need for such 
an invasive procedure. Axonal spheroids with pigmented glia 
is currently considered to be a progressive incurable WMD, 
though case studies have suggested that haematopoietic stem 
cell transplantation may be beneficial [17, 18]. Although the 
mechanism of this treatment is not entirely understood, it is 
thought that haematopoietic stem cell transplantation may lead 
to replenishment of a healthy microglial population.
Case 5: WMD from COVID-19 post-anoxic 
encephalopathy 
A 70-year-old man developed COVID-19 pneumonia 
and progressive hypoxaemia requiring intubation, sedation, 
and mechanical ventilation. He developed adult respiratory 
Figure 3. Case 4: MRI of the brain. A. Sagittal T1 MRI shows 
predominantly parietal and frontal lobe cortical atrophy with ex 
vacuo ventriculomegaly, and B. thinning of the corpus callosum. 
C. and D. Axial T2 FLAIR MRI shows hyperintensities in the peri-
ventricular and subcortical regions, with sparing of the cortical
U-fibres (arrows)
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distress syndrome and multiorgan failure including renal 
failure and critical illness myopathy on electromyography. He 
eventually received a tracheostomy after his nasopharyngeal 
COVID-19 test was negative and developed SARS-CoV-2 IgG 
antibodies. After a month of hospitalisation, he was trans-
ported to a chronic care facility for rehabilitation, but suffered 
unresponsiveness and severe hypoxia (pulse oximeter in the 
70s) despite increasing his fractional inspired oxygen (FiO2). 
Arterial blood gas showed an acute severe acidosis, with pH 
of 6.95, PaCO2 of 135, and PaO2 of 95 on 100% FiO2. He later 
developed left facial focal twitching; electroencephalogram 
confirmed generalised periodic discharges. Non-contrast CT 
head imaging showed hypodense frontal white matter with 
a subtle loss in grey-white matter differentiation (Supplemental 
Fig. 2A). T2 FLAIR MRI of the brain showed severe bilateral 
hyperintensities in the subcortical and cortical white matter, 
particularly in the left occipital cortical regions, consistent 
with global hypoxic-brain injury (Supplemental Fig. 2B). 
Susceptibility weighted imaging (SWI) showed diffuse micro-
haemorrhages (Supplemental Fig. 2C). Given his overall poor 
prognosis, palliative care was discussed with his family. 
This case demonstrates a straightforward post-hypoxic 
cause of white matter changes similar to cardiac arrest, which 
is a direct neuronal injury to the cortex, white matter neurons, 
and astrocytes.  However, the emergence of COVID-19 cases 
of demyelinating disease have also been reported similar to 
Figure 4. Three-step clinical approach to adult-onset white matter diseases. 
AIDS — acquired immunodeficiency syndrome; CADASIL — cerebral autosomal dominant arteriopathy with subcortical infarcts and leuko-
encephalopathy; CSF — cerebrospinal fluid; NOTCH3 — neurogenic locus notch homolog protein 3; PML — progressive multifocal leukoen-
cephalopathy; WMD - white matter disease
multiple sclerosis with gadolinium enhancement [19]. This 
patient’s MRI of the brain and cervical and thoracic spine with 
and without contrast failed to reveal any contrast enhance-
ment. Multiple microhaemorrhages seen on SWI have also 
been reported in COVID-19, and may represent an under-
lying microvasculopathy of the disease. In one of the largest 
neuroimaging studies on COVID-19, 35% of patients had 
non-specific white matter changes noted on CT and/or MRI. 
Some patients were also noted to have acute cerebrovascular, 
hypoxic, and post-ictal changes on neuroimaging [20]. 
Given the global prevalence of COVID-19, and assuming 
the 35% baseline WMD changes seen on neuroimaging, these 
changes may in fact reflect small vessel disease secondary to 
chronic hypertension. However, clinicians should be aware of 
other autoimmune/demyelinating variants where the history 
and imaging are supportive of it.  
Discussion
WMDs comprise an array of clinical, genetic, and patho-
physiologically distinct entities, including acquired progressive 
diseases such as demyelinating disorders and nonspecific cer-
ebrovascular WMD seen with hypertension, diabetes mellitus, 
and renal dysfunction (Tab. 2). Some cases of WMD may rep-
resent an undefined genetic syndrome or variants of unknown 










• Detailed clinical history: acute, subacute, chronic, progressive, family, and ethnic history
• Physical examination: neurological examination for central and peripheral nervous systems
• Confluent bilateral or discrete neuroanatomic brain region involvement
• Specificity to certain brain regions (e.g. anterior temporal lobe involvement in CADASIL and non-gadolinium 
   enhancement in PML, AIDS, and other immunocompromised states)
• Spinal cord or other involvement (e.g. adrenoleukodystrophy)
• Based on the clinical history, physical examination, and neuroimaging review, selective genetic testing (NOTCH3 for 
 CADASIL) could be considered, as well as serum or CSF testing depending on the phenotype and neuroimaging  
   pattern (Table 2)
• Pathology (brain biopsy and/or post-mortem examination) can be considered for some disorders including sporadic, 
   slow neurodegenerative, progressive, and unknown WMD type
Three-Step Clinical Approach to Adult-Onset White Matter Diseases
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Table 2. Adult- and paediatric-onset white matter disease
Inherited adult-onset WMD






Clinical features MRI (T1, T2, FLAIR) increased 
signal
MLD† AR ARSA en-
zyme
ARSA • Behavioural and psychiatric 
changes
• Cognitive decline and gait 
disturbance
• Peripheral neuropathy
• Diffuse, symmetric WMH (T2, FLAIR)
• Abnormal periventricular myelin (T2, 
FLAIR)
• Sparing of subcortical U-fibres
• T1 increased signal
CADASIL AD Genetic 
testing
NOTCH3 • Atypical migraine; recurrent 
ischaemic events 
• Cognitive decline
• Nodular to diffuse periventricular 
WMH
• Anterior temporal lobe WMH (T2, 
FLAIR) and prolonged T1 and T2 
relaxation times
HDLS AD Molecular 
genetic 
testing
CSF1R • Behavioural changes, ataxia, 
seizures
• Pyramidal and extrapyramidal 
signs
• Bilateral, asymmetric, confluent WMH 
(T2, FLAIR)
• Frontal predominance
Krabbe disease‡ AR GALC en-
zyme




• Centrum semiovale, periventricular, 
and deep subcortical WMH (T2, 
FLAIR)
X-ALD X-linked VLCFA mea-
surement
ABCD1 • Dementia, ataxia, spastic para-
paresis
• Neurogenic bladder, bowel 
dysfunction, sexual dysfunction, 
peripheral neuropathy
• Occipital predominance for WMH 
(T2, FLAIR)
• Splenium of corpus callosum and 
posterior limb of internal capsule 
involvement
• Spinal cord atrophy
VWM AR CSF asialo-
transferrin
EIF2B1-5 • Ataxia, spastic paraparesis
• Cognitive decline, depression
• Diffuse WMH especially infratentorial 
(T2, FLAIR)
• Marked diffuse atrophy of brain with 
ex vacuo ventriculomegaly, cerebel-
lum, and corpus callosum
Tay-Sachs disease AR β-HEXA 
enzyme
HEXA • Psychosis, mood disorders
• Cognitive decline






Clinical features MRI (T2 FLAIR) findings
Acute toxic leuko-
encephalopathy 













• Pseudobulbar speech, ataxia
• Pyramidal tract signs, hyperacti-
ve reflexes
• Stretching spasms, akinetic 
mutism, central pyrexia
• Diffuse, symmetric WMH
• Cerebellum, posterior cerebrum, 
and posterior limbs of the internal 
capsule involvement
• Posterior-anterior supratentorial 
















• Mental deterioration, seizures, 
nystagmus, focal neurological 
deficits
• Catatonic state or ‘khatatonia’ 
from khat, an amphetamine-like 
substance 
• Diffuse, bilateral, symmetrical lesions 
in the subcortical white matter and 
corpus callosum
• Sparing of the U-fibres and basal 
ganglia
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• Mental deterioration, vision loss, 
speech difficulty
• Ataxia, paralysis, seizures
• Multifocal, bilateral, asymmetrical 










• Altered mental status, headache
• Abnormal visual perception
• Seizures









Clinical features MRI (T2 FLAIR) findings
Alexander Disease AD Molecular 
genetic 
testing
GFAP • Dysphagia, dysarthria, dysp-
honia
• Spastic paraplegia, palatal myoc-
lonus, tremor
• Autonomic dysfunction
• Diffuse, symmetric WMH involving 
the frontoparietal regions
• Atrophy of the medulla and upper 
cervical cord




ASPA • Macrocephaly, lack of head 
control
• Hypotonia
• Diffuse, symmetric WMH in the sub-
cortical areas
• Bilateral globus pallidus involvement
PMD X-linked Genetic 
testing
PLP1 • Ataxia, spasticity, hypotonia
• Cognitive decline
• Diffuse WMH, with cerebellum and 
brain stem involvement
ABCD1 — peroxisomal ABC half-transporters ALDP; AD — autosomal dominant; AIDS — acquired immunodeficiency syndrome; AR — autosomal recessive; ARSA — arylsulfatase A; ASPA — aspartoacylase; 
CADASIL — cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CSF — cerebrospinal fluid; CSF1R — colony stimulating factor 1 receptor; EIF2B1-5 — eukaryotic 
translation initiation factor 2B; FLAIR — fluid-attenuated inversion recovery; GALC — galactosylceramidase; GFAP — glial fibrillary acidic protein; HDLS — hereditary diffuse leukoencephalopathy with neuroa-
xonal spheroids; HEXA — hexosaminidase; HIV — human immunodeficiency virus; JC — John Cunningham; MLD — metachromatic leukodystrophy; MRI — magnetic resonance imaging; NOTCH3 — neuroge-
nic locus notch homolog protein 3; PLP1 — proteolipid protein 1; PMD — Pelizaeus-Merzbacher Disease; PML — progressive multifocal leukoencephalopathy; RPLS — reversible posterior leukoencephalopathy 
syndrome; VLCFA — very long chain fatty acid; VWM — vanishing white matter disease; WMH — white matter hyperintensity; X-ALD — x-linked adrenoleukodystrophy 
†Late infantile MLD characterised by weakness hypotonia, dysarthria, spasticity, seizures, compromised vision and hearing; Juvenile MLD characterised by decline in school performance, behavioural problems; 
MRI changes are similar to adult disease 
‡Paediatric-onset Krabbe Disease characterised by progressive neurological deterioration, muscle hypertonicity, irritability, and peripheral neuropathy
Table 2 cont. Adult- and paediatric-onset white matter disease
not known to be associated with certain diseases [1, 13, 21–24]. 
Variants of unknown significance are challenging since they 
might or might not represent actual genetic pathogenicity to 
the patient’s condition [25]. In rare or sporadic gene mutations, 
there may not be an adequate number of global cases to know 
whether the gene variant of unknown significance in question 
is or is not related. While MRI and advanced genetic testing aid 
in the diagnosis of WMD, atypical cases of unknown aetiology 
present a continuing challenge. 
We recommend a systematic approach to these patients. 
We have drawn up several steps to increase the likelihood of 
reaching an accurate diagnosis (Fig. 4).
Step 1: Detailed history and neurological 
examination
A methodical approach to WMD is critical to establish an 
aetiological diagnosis. We suggest a process consisting of a de-
tailed history and a comprehensive neurological examination 
with neuropsychological testing. 
The detailed history should include a family history or 
a pedigree to better understand the patterns of inheritance 
(e.g. autosomal dominant, autosomal recessive, X-linked, 
or sporadic) in efforts to obtain cost-effective genetic screen-
ing. Family history is thus helpful in diagnosing inherited 
WMDs. Nonetheless, patients often provide an incomplete 
family history, limiting the sensitivity of potential selected 
genetic testing. Also, family history is not just pedigree-based, 
but requires detailed investigation into the ethnic background. 
For example, asking about a particular ethnic history of Ashke-
nazi Jewish (neuronal ceroid lipofuscinosis), Asian-Indian, or 
Turkish (Behçet syndrome) descent may help to differentiate 
specific forms of leukoencephalopathy [1]. The demographics 
of Case 2 revealed no such ethnic association. 
In addition, it is important to obtain where possible a preg-
nancy and perinatal history, as white matter abnormalities 
and hypomyelination can result from exposure to alcohol, 
methamphetamine, and cocaine. [26–29]
Neurological signs and symptoms, including peripheral 
neuropathy, cerebellar ataxia, spastic weakness, and dystonic 
dyskinetic movements, which may be found in specific forms 
of WMD [1], should be explored because they may provide 
additional information to the diagnosis. Progressive unilateral 
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symptoms in the presence of drug-resistant focal epilepsy and 
cognitive decline raises the possibility of Rasmussen enceph-
alitis. The absence of one or a group of symptoms does not 
exclude WMD [1]. Case 2 presented with various symptoms, 
but tests for specific forms of WMD were negative. 
The COVID-19 pandemic has emerged with increasing 
reports of devastating diencephalic encephalitis. While 
WMD might be occurring from this disease, we are unaware 
of any formal study. COVID-19 neurological manifestations 
reported to date include: central nervous system manifes-
tations (dizziness, headache, stroke, epileptic seizures, and 
impaired consciousness secondary to acute encephalopathy, 
encephalitis, and necrotising haemorrhagic encephalopathy); 
peripheral nervous system manifestations (impairment of 
taste, smell, and vision, and peripheral neuropathy); and 
skeletal muscular injury manifestations including rhabdomy-
olysis and myalgia [4, 6]. The neurological manifestations of 
COVID-19 according to one study depends on the severity 
of the overall disease burden, and there are reports of the 
virus having neurotropism. We are therefore uncertain as to 
whether the novel coronavirus causes WMD. This is likely 
to be an area that warrants study.
Step 2: Careful review of the neuroimaging 
patterns of WMD
Careful review of the neuroimaging patterns of WMD is 
important. MRI of the brain is fundamental in the diagnostic 
workup of WMDs and reliably classifies WMD by identifying 
distinct structural pattern involvement specific to a disease 
entity [30, 31]. An MRI algorithm has been discussed [32] 
and subdivides MRI characteristics according to 1) prominent 
T2-hyperintensity and T1-hypointensity WMD, further subdi-
vided into confluent and multifocal patterns, and 2) hypomy-
elination with mild T1 hyperintensity and T2 hyperintensity, 
T1 isointensity, or mild T1 hypointensity, further subdivided 
into peripheral or no peripheral nervous system involvement. 
MRI discriminators have also been defined [32] and 
help to differentiate confluent and isolated patterns from 
multifocal ones. While inherited WMDs often present with 
bilateral, symmetric, and confluent MRI patterns, acquired 
cases demonstrate a multifocal, isolated, and asymmetric pat-
tern; however, these disease-specific patterns may sometimes 
overlap (e.g. the bilateral, symmetric, and confluent pattern of 
human immunodeficiency virus / acquired immunodeficiency 
syndrome [HIV/AIDS] encephalopathy). In patients older 
than 18-months, other MRI discriminators help differentiate 
T2-hyperintensities due to delayed myelination or permanent 
hypomyelination from other forms of WMD and help localise 
confluent patterns to the frontal, parieto-occipital, periven-
tricular, subcortical, or posterior fossa regions. Furthermore, 
while an MRI algorithm may be helpful in the diagnosis of 
WMD, the MRI brain findings in Case 2 remained stable 
despite progressive symptoms, thus impeding our efforts to 
make an aetiological diagnosis.
The pattern of WMD, combined with the clinical history, 
will help guide the approach to a more advanced laboratory or 
genetic testing. Abrupt, stroke-like, or multiple sclerosis-like 
attacks are completely different from a slowly progressive 
WMD. Nonspecific WMD patterns associated with uncon-
trolled hypertension and renal failure, which are amenable to 
education and risk factor management, should be identified 
and differentiated from specific, adult-onset, acquired WMDs. 
These include acute toxic WMDs from methamphetamine use 
and the inhalation of heroin vapour (e.g. chasing the dragon 
leukoencephalopathy), HIV/AIDS, progressive multifocal 
leukoencephalopathy from John Cunningham (JC) virus, and 
remote multiple sclerosis.
Since the COVID-19 pandemic onset, there has been 
a rapid increase in the number of studies reporting the neu-
roimaging findings of SARS-CoV-2 given the reports of neural 
tissue tropism. In patients with COVID-19, non-contrast CT 
head imaging has demonstrated symmetric hypoattenuation 
within the bilateral medial thalami with negative CT angio-
gram and venogram, while on T2 FLAIR MRI of the brain, 
hyperintensities have been reported within the bilateral 
medial temporal lobes and thalami with evidence of diffuse 
microhaemorrhages on SWI [33]. Based on these preliminary 
reports, a ‘diencephalic encephalitis’ pattern seems to suggest 
a severe viral attack on these deep brain structures. 
As described above, neuroimaging in COVID-19 patients 
have shown a prevalence of 35% of non-specific white matter 
changes, and clinicians should be aware that demyelinating 
WMD variant could be underreported. Other reported 
findings on MRI of the brain in COVID-19 patients include 
cortical signal abnormalities on FLAIR, cortical diffusion 
restriction, leptomeningeal enhancement, and cortical bloom-
ing artifact [34].
Step 3: Ancillary laboratory testing, genetic 
testing, and pathology
As illustrated in the cases above, some patients with WMD 
can be diagnosed simply by means of Steps 1 and 2 (detailed 
history, neurological examination, and review of neuroim-
aging). However, as in Case 1, selected genetic testing for 
NOTCH3 gene mutation can yield a definitive diagnosis of 
CADASIL. While single-gene tests or whole genome sequenc-
ing can be considered, we generally recommend performing 
these in conjunction with a medical geneticist; if a genetic 
disorder is discovered, genetic counselling is often needed 
for the patient and offspring. Furthermore, optical coherence 
tomography (OCT) and OCT-angiography can be useful in 
measuring vessel density and thickness in the early detection 
of CADASIL white matter changes [35, 36].
Progressive multifocal leukoencephalopathy due to JC 
virus is an important differential diagnosis in immunocom-
promised adults. JC virus PCR in CSF is typically high enough 
to form the majority of diagnoses, albeit negative in rare cases 
[37]. On the other hand, while isolated case reports have 
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indeed detected SARS-CoV-2 RNA in the CSF [38], other 
studies have been unable to isolate the virus and have only 
found an elevated total protein count, despite having a positive 
nasal swab and in the presence of neurological symptoms and/
or positive neuroimaging [5, 34, 39].
Brain biopsy has been proposed in some cryptogenic 
WMD cases, but only yields a diagnosis 29-65% of the time, 
although this figure can be as high as 78% when a more discrete 
or localised lesion is identified on neuroimaging [40]. Brain 
biopsy in patients with WMD may be useful when the clinical 
state is deteriorating, when all tests have failed to provide 
a diagnosis, or when a treatable condition is suspected. 
For progressive, neurodegenerative cases of WMD of 
unknown cause, autopsy remains the standard criterion 
for postmortem diagnosis [41–44]. It can better inform 
the offspring and guide family planning, contribute to our 
scientific understanding of WMD, and lead to better treat-
ments. In Case 2, after multiple discussions with our patient 
about a brain biopsy, the patient refused to proceed given the 
uncertainty that a biopsy would yield a treatable diagnosis. 
The patient and her family understood that a final diagnosis 
after death via autopsy could be definitive, and they agreed 
to that approach. 
We propose that undiagnosed patients with WMD be 
entered into multicentre National Organisation for Rare 
Diseases registries to help researchers across the globe make 
new discoveries that will hopefully translate into future cures.
Conclusion
While paediatric WMDs historically have a well-defined 
and literature-based clinical-laboratory approach to diagnosis, 
adult-onset WMD remains an important yet pathologically 
diverse radiographic phenotype, with different and distinct 
neuropathologies among the various subtypes of WMD. 
We propose a three-step clinical approach to adult-onset 
WMD: 1) detailed history collection, including family and 
ethnic history, and neurological examination; 2) careful re-
view of neuroimaging patterns; and 3) selective consideration 
of laboratory, genetic, and pathological means of diagnosis. 
The combined clinical-imaging-laboratory approach to 
adult-onset WMD must continue to evolve if we are to shed 
more light on these conditions, and discover better therapies 
for cerebral WMDs.
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